Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2019 Jul 08;: Authors: Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D’Haens GR Abstract OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using…

Read More

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring.

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring. Gastroenterology. 2019 Jun 10;: Authors: Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R, Yerushalmi B, Shamir R Abstract BACKGROUND & AIMS: Proactive monitoring of drug trough concentrations and antibodies against drugs might help determine whether patients are likely to respond to treatment and increase efficacy. We investigated whether proactive drug monitoring is associated with higher rates…

Read More

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis. J Crohns Colitis. 2019 May 15;: Authors: Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG Abstract BACKGROUND: Adalimumab is administered via a pre-filled syringe or spring-loaded pen. In a previous study in Crohn’s disease, higher drug levels were observed in syringe users. The aim of this study was to evaluate the…

Read More

Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).

Related Articles Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). J Gastroenterol. 2019 Apr 30;: Authors: Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T, DIAMOND2 Study Group Abstract BACKGROUND: The risk:benefit ratio of concomitant use of thiopurines with scheduled adalimumab (ADA) maintenance therapy for Crohn’s disease is…

Read More

Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.

Related Articles Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC, Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Abstract BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab…

Read More

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study.

Related Articles Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study. J Crohns Colitis. 2019 Mar 01;: Authors: Casteele NV, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A Abstract BACKGROUND: Therapeutic drug monitoring is used to optimize adalimumab therapy in patients with Crohn’s disease (CD). However, the interindividual variability in drug absorption and the quantitative effect on drug clearance of antiadalimumab antibodies (AAA), measured with a drug resistant assay, is unclear. AIM:…

Read More

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study. J Crohns Colitis. 2019 Jan 25;13(Supplement_1):S616 Authors: Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Boureille A, Moreau J, Buisson A, Roblin X, Nachury M, Zappa M, Lambert J, Bouhnik Y, GETAID-MICA study group Abstract doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the ‘Poster presentations’ section of the main abstract book has been withdrawn and…

Read More

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies.

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies. J Crohns Colitis. 2019 Feb 09;: Authors: Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF Abstract Background and Aims: Analyses of Crohn’s Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort. Methods: Data were pooled…

Read More

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn’s disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn’s disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). J Crohns Colitis. 2019 Feb 08;: Authors: Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract Background: Combining a thiopurine with the human anti-tumor necrosis factor- monoclonal antibody adalimumab for Crohn’s…

Read More

Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease.

Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Feb 07;: Authors: Dai C, Jiang M, Yu JH PMID: 30753387 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30753387?dopt=Abstract

Read More
<< Go Back